

Manufacturing Strategies for Biosimilars

Anne Marie de Jonge-Schuermans

Global Head of Biologics & Injectables Operations, Sandoz AG, Switzerland
anne_marie.de_jonge_schuermans@sandoz.com

Manufacturing strategies for biosimilars differ from those for originator Biological Medicines for various reasons. Therefore, we will touch on a wide range of aspects such as healthcare economics, patient benefits, intellectual property, biosimilarity, cost of goods, manufacturing technologies, -systems and -locations. Furthermore, critical challenges in technical development and manufacturing biosimilars will be addressed, including cold chain management, scale-up, and safe handling of biosimilars, all while balancing cost and time efficiency with regulatory compliance.